Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs.Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; ...
Source LinkBiogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs.Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; ...
Source Link
Comments